Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Chronic urticaria: novel clinical and serological aspects
Autore:
Asero, R; Tedeschi, A; Lorini, M; Salimbeni, R; Zanoletti, T; Miadonna, A;
Indirizzi:
Osped Caduti Bollatesi, Ambulatorio Allergol, I-20021 Bollate, MI, Italy Osped Caduti Bollatesi Bollate MI Italy I-20021 -20021 Bollate, MI, Italy Politecn Milan, Osped Maggiore, IRCCS, Div Med 3,Allergy Unit, Milan, Italy Politecn Milan Milan Italy IRCCS, Div Med 3,Allergy Unit, Milan, Italy AO Fatebenefratelli, Div Med & Pneumol, Milan, Italy AO Fatebenefratelli Milan Italy atelli, Div Med & Pneumol, Milan, Italy ICP, Allergy Unit, Milan, Italy ICP Milan ItalyICP, Allergy Unit, Milan, Italy
Titolo Testata:
CLINICAL AND EXPERIMENTAL ALLERGY
fascicolo: 7, volume: 31, anno: 2001,
pagine: 1105 - 1110
SICI:
0954-7894(200107)31:7<1105:CUNCAS>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC IDIOPATHIC URTICARIA; FC-EPSILON-RI; HISTAMINE-RELEASING ACTIVITY; ANTI-IGE AUTOANTIBODIES; AUTOLOGOUS SERUM; SKIN REACTIVITY; HEPARIN; RELEASABILITY; RECEPTOR; BINDING;
Keywords:
basophils; histamine release; heparin; serum; urticaria;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Asero, R Osped Caduti Bollatesi, Ambulatorio Allergol, Via Piave 20, I-20021 Bollate, MI, Italy Osped Caduti Bollatesi Via Piave 20 Bollate MI Italy I-20021 taly
Citazione:
R. Asero et al., "Chronic urticaria: novel clinical and serological aspects", CLIN EXP AL, 31(7), 2001, pp. 1105-1110

Abstract

Background Recently, distinct studies have shown that: (a) chronic idiopathic urticaria (CIU) is autoimmune in 30-50% of cases; (b) in patients with CIU the autologous serum skin test is inhibited by heparin; and (c) basophil histamine release induced in vitro by CIU sera maybe complement-dependent. Objective To carry out a comprehensive clinical and serological study on CIU based upon these observations. Methods Three hundred and six adults with CIU underwent intradermal (ID) test with autologous serum; 57 of them with autologous heparinized plasma aswell. Sera from 121 patients (plasmas from 17) were employed to induce in vitro histamine release from basophils of normal donors. The effects of heating (56 degreesC, 60 min), filtration through membrane, and preincubation with heparin were evaluated as well. Results Autologous serum and plasma induced a weal and flare reaction in 205 out of 306 (205/306; 67%) and in 8/57 (14%) patients, respectively. Positive plasma skin tests were observed only in patients showing strongly positive serum skin tests. Plasma did not elicit any skin reaction in 3/3 patients with dermatographism who showed a positive intradermal test with saline. Sera from 20/121 (16.5%) patients induced significant histamine release from basophils of normal donors. 19/20 sera were from patients with a positive intradermal test; thus, basophil histamine release assay was positive in19/87 (21.8%) patients with a positive serum skin test. Heating at 56 degreesC x 1 h markedly reduced the histamine-releasing activity of both serum and plasma from in vitro reactors. Ultrafiltered fractions > 100 kDa of both sera tested retained the histamine-releasing activity, whereas fractions < 100 kDa were not able to induce any histamine release. Heparin dose-dependently inhibited histamine release induced by sera and plasma, and by basophil agonists such as anti-IgE, formyl-methionyl-leucyl-phenilalanine, and interleukin (IL)-3. Conclusions 67% of our patients with CIU showed a positive autologous serum skin test. Sera from about 20% of those positive on autologous serum skintest induced histamine release from normal basophils in vitro probably as a consequence of the presence of functional autoantibodies. The marked difference between in vivo and in vitro findings could reflect the existence ofa mast cell-specific histamine-releasing factor which does not release histamine from basophils of healthy blood donors. However, it might be also the result of in vivo priming of patients' cutaneous mast cells or of heterogeneity of basophil donors. At least in some cases complement seems essential for histamine-releasing activity of serum from patients with CIU. Heparininhibits histamine release from both basophils (in vitro) and mast cells (in vivo), probably acting directly at a cellular level.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 23:24:11